Bristol-myers Squibb Compnay

Vaishali Shah

Suzanne J Suchard

Marek Honczarenko

Karen D Price

Xiaoni Liu

Rong Shi

Diane E Shevell

Wendy L Trigona

Linda M Gustavson

Lixin Lang

Urvi Aras

Christine Kratt

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

Methods of treating autoimmune disease using a domain antibody directed against CD40L

A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single Vor Vdomain and an Fc domain.

Method of using antibody polypeptides that antagonize CD40 to treat IBD

Growing community of inventors

Pennington, NJ, United States of America

Vaishali Shah